News - MedTech & Diagnostics
What Philips’ new report adds to the ‘AI in healthcare’ debate

Ten years in, the Future Health Index (FHI) lands with sharp relevance – less a forecast, more a mirror. In a healthcare system grappling with the promises and pitfalls of artificial intelligence (AI), Shehaan Fernando, Interim Managing Director of Philips ANZ, joins the Health Industry Hub podcast to unpack what the latest data reveals.
Three government-led consultations on AI in healthcare have taken place in just the past year, culminating in a Department of Health report released in July. So, what additional value does the FHI report bring to the ongoing debate?
From workforce readiness to ethical grey zones, and from patient trust to policy ambition, this conversation delves into the themes that define how we use AI “to bend the cost curve”. It also dares to confront a more uncomfortable insight that is essential for healthcare leaders to face.
With the re-elected Labor government likely to remain in power for the next six years, the window to move from talk to action is wide open. Navigating what’s next will demand more than algorithms – it will demand backbone for sustainable implementation so that we can finally move beyond the cycle of ‘more pilots than Qantas’.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News - MedTech & Diagnostics

CEO roundtable to tackle private health deadlock
Australia’s largest medical indemnity provider representing 95,000 doctors, Avant Mutual, is stepping into the private healthcare policy battlefield, convening 36 […]
MoreNews - Pharmaceuticals

Rare cancer patients pay the price of policy paralysis: New report
Rare Cancers Australia (RCA) is set to release a new report exposing the staggering disparities faced by Australians with rare […]
MoreNews - Pharmaceuticals

PBS listing delivers first IL-4/IL-13 inhibitor for young children with severe asthma
From 1 September, children aged 6–11 years with severe and uncontrolled asthma driven by type 2 inflammation will have access […]
MoreNews - Pharmaceuticals

Pfizer’s pneumococcal vaccine funded after a blurry 1000+ days
From 1 September, Pfizer’s Prevenar 20 (PCV20) officially enters the National Immunisation Program (NIP), becoming the only funded 20-valent pneumococcal […]
More